Other News To Note
Wednesday, November 23, 2011
Amsterdam Molecular Therapeutics NV, of Amsterdam, the Netherlands, received orphan drug designation from the European Medicines Agency for its hemophilia B gene therapy. A Phase I/II trial is ongoing with the treatment, which consists of an adeno-associated viral vector containing the human factor IX gene.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.